Real-world comparison of Ixazomib, lenalidomide and
dexamethasone vs lenalidomide and dexamethasone in relapsed and
refractory multiple myeloma

a 2019

Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma

MINARIK, J.; T. PIKA; J. RADOCHA; A. JUNGOVA; J. STRAUB et al.

Základní údaje

Originální název

Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma

Autoři

Vydání

17th International Myeloma Workshop, 2019

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.298

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00108625

Organizační jednotka

Lékařská fakulta

ISSN

DOI

https://doi.org/10.1016/j.clml.2019.09.448

UT WoS

000491229800445

Klíčová slova anglicky

ixazomib; myeloma; relapsed/refractory

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 14. 4. 2020 10:06, Mgr. Tereza Miškechová

Anotace

V originále

We have performed a face to face comparison of all-oral triplet ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS).

Návaznosti

NV17-29343A, projekt VaV

Název: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu

Citovat

MINARIK, J.; T. PIKA; J. RADOCHA; A. JUNGOVA; J. STRAUB; T. JELINEK; Luděk POUR; P. PAVLICEK; M. MISTRIK; Lucie BROŽOVÁ; P. KRHOVSKA; K. MACHALKOVA; P. JINDRA; I. SPICKA; H. PLONKOVA; Martin ŠTORK; J. BACOVSKY; L. CAPKOVA; M. SYKORA; P. KESSLER; L. STEJSKAL; A. HEINDORFER; J. ULLRYCHOVA; V. MAISNAR a R. HAJEK. Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma. In 17th International Myeloma Workshop. 2019. ISSN 2152-2650. Dostupné z: https://doi.org/10.1016/j.clml.2019.09.448.

@proceedings{1644976,
   author = {Minarik, J. and Pika, T. and Radocha, J. and Jungova, A. and Straub, J. and Jelinek, T. and Pour, Luděk and Pavlicek, P. and Mistrik, M. and Brožová, Lucie and Krhovska, P. and Machalkova, K. and Jindra, P. and Spicka, I. and Plonkova, H. and Štork, Martin and Bacovsky, J. and Capkova, L. and Sykora, M. and Kessler, P. and Stejskal, L. and Heindorfer, A. and Ullrychova, J. and Maisnar, V. and Hajek, R.},
   booktitle = {17th International Myeloma Workshop},
   doi = {https://doi.org/10.1016/j.clml.2019.09.448},
   keywords = {ixazomib; myeloma; relapsed/refractory},
   language = {eng},
   title = {Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma},
   url = {https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31835-X/abstract},
   year = {2019}
}

TY  - CONF
ID  - 1644976
AU  - Minarik, J. - Pika, T. - Radocha, J. - Jungova, A. - Straub, J. - Jelinek, T. - Pour, Luděk - Pavlicek, P. - Mistrik, M. - Brožová, Lucie - Krhovska, P. - Machalkova, K. - Jindra, P. - Spicka, I. - Plonkova, H. - Štork, Martin - Bacovsky, J. - Capkova, L. - Sykora, M. - Kessler, P. - Stejskal, L. - Heindorfer, A. - Ullrychova, J. - Maisnar, V. - Hajek, R.
PY  - 2019
TI  - Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
KW  - ixazomib
KW  - myeloma
KW  - relapsed/refractory
UR  - https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31835-X/abstract
L2  - https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31835-X/abstract
N2  - We have performed a face to face comparison of all-oral triplet ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS).
ER  -

MINARIK, J.; T. PIKA; J. RADOCHA; A. JUNGOVA; J. STRAUB; T. JELINEK; Luděk POUR; P. PAVLICEK; M. MISTRIK; Lucie BROŽOVÁ; P. KRHOVSKA; K. MACHALKOVA; P. JINDRA; I. SPICKA; H. PLONKOVA; Martin ŠTORK; J. BACOVSKY; L. CAPKOVA; M. SYKORA; P. KESSLER; L. STEJSKAL; A. HEINDORFER; J. ULLRYCHOVA; V. MAISNAR a R. HAJEK. Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma. In \textit{17th International Myeloma Workshop}. 2019. ISSN~2152-2650. Dostupné z: https://doi.org/10.1016/j.clml.2019.09.448.

Přehled o publikaci